FDA.reportPublic FDA data

Lumryz 4500 MG Granules for Oral Suspension

RxCUI
2636828
RxNorm name
Lumryz 4500 MG Granules for Oral Suspension
Display name
Lumryz 4500 MG Granules for Oral Suspension
Full name
Lumryz 4500 MG Granules for Oral Suspension
Term type
SY
Status
DailyMed mapping
Updated
2026-06-04 23:38:47

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
10e5e40c-52f3-4c73-8a34-2c29c690a934Lumryz 4.5 GM Granules for extended release Oral Suspension [PSN] · sodium oxybate 4500 MG Granules for Oral Suspension [Lumryz] [SBD] · Lumryz 4.5 GM (equivalent to 3.7 GM oxybate) Granules for Oral Suspension [SY] · Lumryz 4500 MG Granules for Oral Suspension [SY]410These highlights do not include all the information needed to use LUMRYZ™ safely and effectively. See full prescribing information for LUMRYZ. LUMRYZ (sodium oxybate) for extended-release oral suspension, CIII Initial U.S. Approval: 200220251204